Company Rankings

2025 saw some shakeups to the sales rankings of big pharma, but with widespread major asset patent losses, 2026 and beyond could prove even more turbulent.

perspectives 2026

After no M&A transactions reached the $5bn threshold in 2024, J&J, Pfizer, Novartis and Merck & Co. all signed on for biopharma takeouts valued at $9bn or higher in 2025.

data

AstraZeneca, Lilly, Novo Nordisk and Amgen all moved up in the rankings on the Scrip 100 leaderboard powered by impressive double-digit growth.